Published in Radiology on October 01, 2014
Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. Am J Gastroenterol (2016) 1.15
Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol (2015) 0.87
Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. Korean J Radiol (2016) 0.83
Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study. Medicine (Baltimore) (2016) 0.80
Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. Eur Radiol (2016) 0.79
Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI. Liver Cancer (2015) 0.79
Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol (2016) 0.78
Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget (2016) 0.78
Multimodal Imaging of Nanocomposite Microspheres for Transcatheter Intra-Arterial Drug Delivery to Liver Tumors. Sci Rep (2016) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (2016) 0.76
Contrast Enhanced MRI in the Diagnosis of HCC. Diagnostics (Basel) (2015) 0.76
Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 2. Radiol Bras (2017) 0.75
Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. Radiol Bras (2017) 0.75
Triple Arterial Phase MR Imaging with Gadoxetic Acid Using a Combination of Contrast Enhanced Time Robust Angiography, Keyhole, and Viewsharing Techniques and Two-Dimensional Parallel Imaging in Comparison with Conventional Single Arterial Phase. Korean J Radiol (2016) 0.75
Imaging Techniques for Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) (2015) 0.75
MRI features of hepatocellular carcinoma related to biologic behavior. Korean J Radiol (2015) 0.75
Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents? World J Gastroenterol (2016) 0.75
Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. Korean J Radiol (2017) 0.75
Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. Infect Agent Cancer (2017) 0.75
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid. World J Gastroenterol (2016) 0.75
Magnetic Resonanance Imaging of the Liver (Including Biliary Contrast Agents)-Part 2: Protocols for Liver Magnetic Resonanance Imaging and Characterization of Common Focal Liver Lesions. Semin Roentgenol (2016) 0.75
Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol (2017) 0.75
Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol (2016) 0.75
Hepatic stiffness measurement by using MR elastography: prognostic values after hepatic resection for hepatocellular carcinoma. Eur Radiol (2016) 0.75
How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis. Liver Cancer (2017) 0.75
Magnetic Resonance Imaging of Primary Hepatic Malignancies in Patients With and Without Chronic Liver Disease: A Pictorial Review. Cureus (2017) 0.75
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75
The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut (2009) 6.50
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Diffusion-weighted MR imaging of the liver. Radiology (2010) 3.50
Updated treatment approach to hepatocellular carcinoma. J Gastroenterol (2005) 3.43
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology (2012) 2.53
Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology (2012) 2.36
Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol (2009) 2.23
MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology (2008) 2.19
The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology (2006) 2.18
Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology (2009) 2.10
Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology (2010) 1.95
Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology (1998) 1.90
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol (2009) 1.89
MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology (2003) 1.85
Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation (2000) 1.79
The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol (2011) 1.79
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology (2010) 1.67
Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology (2010) 1.61
Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol (2011) 1.57
Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma. Radiology (1999) 1.54
Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging. Liver Transpl (2012) 1.51
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47
Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol (1997) 1.47
Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol (2012) 1.46
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol (2010) 1.44
Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res (1992) 1.44
Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology (2011) 1.43
MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int (2011) 1.42
Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol (2012) 1.37
Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology (2001) 1.37
Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis Markers (2011) 1.36
Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol (2009) 1.36
Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol (2010) 1.33
Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr (2001) 1.31
Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol (2010) 1.31
The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol (2011) 1.29
Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging (2003) 1.24
Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology (2005) 1.23
Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. J Magn Reson Imaging (2010) 1.23
Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol (2011) 1.22
Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor. Korean J Radiol (2010) 1.21
Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol (2011) 1.18
Dynamic CT for detecting small hepatocellular carcinoma: usefulness of delayed phase imaging. AJR Am J Roentgenol (2007) 1.17
Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol (2009) 1.17
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol (2010) 1.17
Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr (2010) 1.16
Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology (1992) 1.16
Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol (2009) 1.16
Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology (2013) 1.15
Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology (2012) 1.14
Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.13
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol (2008) 1.11
Liver lesion detection and characterization: role of diffusion-weighted imaging. J Magn Reson Imaging (2013) 1.11
Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol (2000) 1.10
Histopathology of liver cancers. Best Pract Res Clin Gastroenterol (2005) 1.09
The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol (2001) 1.08
Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology (2008) 1.08
Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology (2013) 1.08
Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology (2012) 1.07
Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol (2006) 1.07
Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. Arch Surg (2002) 1.05
Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol (2009) 1.05
Adenomatous hyperplastic nodules in the cirrhotic liver: differentiation from hepatocellular carcinoma with MR imaging. Radiology (1989) 1.05
Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging (2011) 1.04
Enhancement patterns and signal-intensity characteristics of small hepatocellular carcinoma in cirrhosis: pathologic basis and diagnostic challenges. Eur Radiol (2007) 1.03
Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol (2002) 1.01
CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol (1995) 1.01
Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol (2010) 1.01
Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology (2011) 0.99
Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology (2011) 0.99
Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging (2012) 0.99
Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology (2012) 0.99
Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis (2009) 0.98
Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol (2010) 0.98
Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging (2011) 0.96
Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging (2010) 0.96
Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging (2012) 0.94
Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol (2011) 0.94
Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol (2013) 0.94
18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer (2011) 0.94
SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings. Korean J Radiol (2009) 0.93
Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. AJR Am J Roentgenol (2011) 0.93
Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol (2012) 0.93
Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging (2013) 0.93
The pseudocapsule in hepatocellular carcinoma: correlation between dynamic MR imaging and pathology. Eur Radiol (1999) 0.93
Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol (2006) 0.92
Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology (2005) 0.92
Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology (2010) 0.92
Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cm. Oncology (2007) 0.92
Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol (2012) 0.91
Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging (2008) 4.13
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Heritability of nonalcoholic fatty liver disease. Gastroenterology (2009) 3.17
Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol (2007) 3.17
Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology (2011) 3.08
In vivo characterization of the liver fat ¹H MR spectrum. NMR Biomed (2010) 3.07
Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging (2011) 2.75
Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology (2011) 2.42
CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. Radiographics (2005) 2.37
T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging (2011) 2.27
Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology (2006) 2.23
Fatty liver: imaging patterns and pitfalls. Radiographics (2006) 2.21
Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging (2009) 2.18
Automated registration of sequential breath-hold dynamic contrast-enhanced MR images: a comparison of three techniques. Magn Reson Imaging (2011) 2.15
Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology (2005) 2.14
Advances in pediatric nonalcoholic fatty liver disease. Hepatology (2009) 2.03
Abdominal wall hernias: imaging features, complications, and diagnostic pitfalls at multi-detector row CT. Radiographics (2005) 1.98
Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging (2012) 1.90
SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology (2010) 1.81
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol (2010) 1.70
Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med (2011) 1.67
Reproducibility of MRI-determined proton density fat fraction across two different MR scanner platforms. J Magn Reson Imaging (2011) 1.66
MR imaging of liver fibrosis: current state of the art. Radiographics (2009) 1.62
Disproportionate fat stranding: a helpful CT sign in patients with acute abdominal pain. Radiographics (2004) 1.54
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Optimal phased-array combination for spectroscopy. Magn Reson Imaging (2008) 1.48
Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol (2008) 1.47
Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. Radiographics (2009) 1.46
Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol (2007) 1.42
Cross-sectional imaging of extranodal involvement in abdominopelvic lymphoproliferative malignancies. Radiographics (2007) 1.38
Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol (2008) 1.36
Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol (2010) 1.33
LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology (2014) 1.31
CT appearance of the normal appendix in adults. Eur Radiol (2005) 1.21
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology (2015) 1.18
Cisterna chyli at routine abdominal MR imaging: a normal anatomic structure in the retrocrural space. Radiographics (2004) 1.11
Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol (2012) 1.11
Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics (2008) 1.10
Pediatric nonalcoholic fatty liver disease: a comprehensive review. Adv Pediatr (2010) 1.08
Imaging-based diagnostic systems for hepatocellular carcinoma. AJR Am J Roentgenol (2013) 1.08
MR contrast agents for liver imaging: what, when, how. Radiographics (2006) 1.03
Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology (2014) 1.02
Constraining the initial phase in water-fat separation. Magn Reson Imaging (2010) 1.02
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Robustness of fat quantification using chemical shift imaging. Magn Reson Imaging (2011) 0.99
Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging. J Magn Reson Imaging (2008) 0.95
Hypotensive patients with blunt abdominal trauma: performance of screening US. Radiology (2005) 0.95
Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. J Magn Reson Imaging (2013) 0.94
Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging (2014) 0.94
Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol (2003) 0.94
Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging (2013) 0.94
Hepatobiliary agents and their role in LI-RADS. Abdom Imaging (2015) 0.93
Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics (2011) 0.93
Prediction of esophageal varices in patients with cirrhosis: usefulness of three-dimensional MR elastography with echo-planar imaging technique. Radiology (2014) 0.92
Analysis of recombinant protein expression using localized surface plasmon resonance (LSPR). Biosens Bioelectron (2007) 0.92
Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas. Insights Imaging (2012) 0.92
Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. J Magn Reson Imaging (2011) 0.92
Update on the Liver Imaging Reporting and Data System: What the Pathologist Needs to Know. Adv Anat Pathol (2015) 0.92
Cardiac motion in diffusion-weighted MRI of the liver: artifact and a method of correction. J Magn Reson Imaging (2011) 0.91
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.91
A quantitative approach to sequence and image weighting. J Comput Assist Tomogr (2010) 0.90
Retinoic acid, acting as a highly specific IgA isotype switch factor, cooperates with TGF-β1 to enhance the overall IgA response. J Leukoc Biol (2013) 0.90
Chest radiography with a flat-panel detector: image quality with dose reduction after copper filtration. Radiology (2005) 0.90
Alum Directly Modulates Murine B Lymphocytes to Produce IgG1 Isotype. Immune Netw (2013) 0.89
Cross-sectional investigation of correlation between hepatic steatosis and IVIM perfusion on MR imaging. Magn Reson Imaging (2012) 0.88
Imaging features of perivascular fatty infiltration of the liver: initial observations. Radiology (2005) 0.87
Ovarian imaging by magnetic resonance in obese adolescent girls with polycystic ovary syndrome: a pilot study. Fertil Steril (2005) 0.87
Spatial distribution of MRI-Determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging (2014) 0.86
Technology insight: advances in liver imaging. Nat Clin Pract Gastroenterol Hepatol (2007) 0.86
Radiologic findings of multiple myeloma with gastric involvement: a case report. Korean J Radiol (2002) 0.86
Screening sonography in pregnant patients with blunt abdominal trauma. J Ultrasound Med (2005) 0.85
Effect of echo-sampling strategy on the accuracy of out-of-phase and in-phase multiecho gradient-echo MRI hepatic fat fraction estimation. J Magn Reson Imaging (2013) 0.85
Screening ultrasound in blunt abdominal trauma. J Intensive Care Med (2004) 0.84
Callback and follow-up guidelines for whole-body CT screening. Radiology (2006) 0.84
Current stress induced electrical instability in transparent zinc tin oxide thin-film transistors. J Nanosci Nanotechnol (2012) 0.84
Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology (2017) 0.83
Noninvasive classification of hepatic fibrosis based on texture parameters from double contrast-enhanced magnetic resonance images. J Magn Reson Imaging (2012) 0.83
Carotid arteries: contrast-enhanced US angiography--preliminary clinical experience. Radiology (2003) 0.83
Effect of eucalyptus oil inhalation on pain and inflammatory responses after total knee replacement: a randomized clinical trial. Evid Based Complement Alternat Med (2013) 0.83
Consensus report of the Fifth International Forum for Liver MRI. AJR Am J Roentgenol (2013) 0.82
Treatment of gastrojejunal anastomotic leak with a covered metallic stent. Hepatogastroenterology (2003) 0.82
Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging (2009) 0.81
Effect of shot number on the calculated apparent diffusion coefficient in phantoms and in human liver in diffusion-weighted echo-planar imaging. J Magn Reson Imaging (2009) 0.81
Alendronate-loaded microparticles for improvement of intestinal cellular absorption. J Drug Target (2010) 0.81
Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. J Magn Reson Imaging (2009) 0.81
On confirmation bias in imaging research. J Magn Reson Imaging (2014) 0.81
MRI of the female pelvis using vaginal gel. AJR Am J Roentgenol (2005) 0.80
A new liver explant fixation technique. Arch Pathol Lab Med (2008) 0.80
Evaluation of MRI fat fraction in the liver and spine pre and post SPIO infusion. Magn Reson Imaging (2013) 0.80
Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. Abdom Imaging (2015) 0.79
Studies on the formation of hydrophobic ion-pairing complex of alendronate. Arch Pharm Res (2009) 0.79
LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. AJR Am J Roentgenol (2014) 0.79
CT and MRI of diffuse lobar involvement pattern in liver pathology. Diagn Interv Radiol (2010) 0.79
Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging (2014) 0.79
Treatment with SI000413, a new herbal formula, ameliorates murine collagen-induced arthritis. Biol Pharm Bull (2008) 0.79
Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol (2013) 0.79
Focal eosinophilic infiltration of the liver mimicking hepatocellular carcinoma: case reports. Clin Imaging (2004) 0.78
Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol (2015) 0.78